Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NFLX +2.3% (also Reed Hastings transitioning to Chairman and non-executive director)
Other news:
- AAPG +6.3% (Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines)
- DFS +5% (Capital One (COF) receives final regulatory approvals for acquisition of Discover; provided FDIC updates)
- COF +2.8% (Capital One (COF) receives final regulatory approvals for acquisition of Discover)
- SNY +2.2% (Sanofi and Regeneron (REGN) receive FDA approval of Dupixent as first new targeted therapy in over a decade for chronic spontaneous urticaria)
- PPTA +2% (announces that the Stibnite Gold Project has been selected as a Transparency Project)
- OPRX +1.2% (plans for additional Board of Directors refreshment)
- GB +1.1% (Shift4 (FOUR) extends previously announced tender offer to acquire Global Blue)
- IMVT +1% (Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease and Cutaneous Lupus Erythematosus for IMVT-1402)